Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Share-based Compensation (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Share-based Compensation for 4 consecutive years, with $66119.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 71.75% to $66119.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $671474.0 through Dec 2025, down 32.23% year-over-year, with the annual reading at $671474.0 for FY2025, 32.15% down from the prior year.
  • Share-based Compensation for Q4 2025 was $66119.0 at bioAffinity Technologies, down from $67132.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $326616.0 in Q1 2025, with the low at $26685.0 in Q2 2022.
  • Average Share-based Compensation over 4 years is $159904.2, with a median of $163933.5 recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 538.01% in 2023, then tumbled 71.75% in 2025.
  • Over 4 years, Share-based Compensation stood at $36847.0 in 2022, then skyrocketed by 536.44% to $234510.0 in 2023, then dropped by 0.18% to $234087.0 in 2024, then crashed by 71.75% to $66119.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $66119.0, $67132.0, and $211607.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.